Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab 500 mg for disability progression in RRMS
IRCT20250301064890N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of rituximab in multiple sclerosis (MS), sponsored by Hamadan University of Medical Sciences. Started Mar 2025; status: completed.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20250301064890N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250301064890N1.